Last 20 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -19.80 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 7.54 | 1.78 | 0.97 | 0.97 | 1.68 | 1.71 | 1.14 | 1.08 | 1.01 | 0.87 | 1.14 | 1.16 | 1.33 |
| — | +3.8% | -15.2% | -10.0% | +65.4% | +95.9% | -0.2% | -7.3% | -24.0% | -66.1% | -32.6% | -51.9% | -67.1% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -43.7% | -8.5% | -8.8% | -7.5% | -7.4% | -6.9% | -17.1% | -11.6% | -9.1% | -8.7% | -8.5% | -8.3% | -34.8% |
| — | -22.8% | +48.6% | +35.0% | +18.5% | +20.0% | -101.5% | -39.2% | +74.0% | +7.3% | +2.3% | -0.5% | -436.7% | |
| ROA | -36.0% | -7.1% | -7.4% | -6.4% | -6.3% | -5.9% | -14.1% | -9.2% | -7.3% | -7.1% | -7.0% | -6.8% | -28.1% |
| — | -19.5% | +47.6% | +30.5% | +14.3% | +16.2% | -101.6% | -35.4% | +74.1% | +11.3% | +9.6% | +9.5% | -372.6% | |
| ROIC | -39.2% | -7.6% | -7.8% | -6.8% | -6.4% | -7.3% | -16.7% | -10.5% | -9.0% | -9.2% | -11.9% | -15.7% | -54.0% |
| — | -4.3% | +53.3% | +35.1% | +29.6% | +20.9% | -40.1% | +33.2% | +83.3% | +46.0% | +45.8% | +32.6% | -99.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 5.0% YoY to 10.45x, tightening the short-term liquidity position. Debt/Equity has risen for 5 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.14 | 0.13 | 0.13 | 0.12 | 0.12 | 0.12 | 0.23 | 0.18 | 0.17 | 0.16 | 0.15 | 0.13 |
| — | +18.0% | +11.0% | -44.4% | -30.5% | -29.7% | -24.7% | +52.3% | +31.8% | +12.3% | +127.2% | +116.8% | +225.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 9.84 | 10.45 | 11.04 | 12.35 | 9.84 | 11.00 | 16.79 | 10.14 | 12.26 | 11.45 | 13.90 | 15.59 | 9.13 |
| — | -5.0% | -34.3% | +21.8% | -19.8% | -3.9% | +20.8% | -35.0% | +34.3% | -13.4% | -18.6% | -17.3% | -43.0% | |
| Quick Ratio | 9.84 | 10.45 | 11.04 | 12.35 | 9.84 | 11.00 | 16.79 | 10.14 | 12.26 | 11.45 | 13.90 | 15.59 | 9.13 |
| — | -5.0% | -34.3% | +21.8% | -19.8% | -3.9% | +20.8% | -35.0% | +34.3% | -13.4% | -18.6% | -17.3% | -43.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 20 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonErasca, Inc.'s current P/E is -19.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Erasca, Inc.'s business trajectory between earnings reports.